SACT2 conference was to accelerate the path to new cell therapies in India, encapsulating our collective commitment to advancing the field, striving for excellence, and improving the lives of patients through transformative cell-based therapies. The conference was an overall essence which turned out not only to be informative but transformative as well. SACT 2 event was held in a series of 7 different tracks covering - Discovery, Pre-Clinical, Process Development, CMC/Analytics, Clinical Trial, Logistics, & Commercial Development. The 2nd SACT event also witnessed a Run/Walk where all the delegates and faculty gathered for the conference enthusiastically put up their shoes on for raising awareness about Cell Therapy in India. The run/walk was accelerated with the theme #CellsCanRun. The run/walk was a success with the support of ImPaCCT Foundation. Ayaan Hashmi and Parveen Shahani were honorary guests for the event of Run/Walk.
| International Speaker | Talk Title | Highlights | |
|---|---|---|---|
 |
Dr. Rohan Kamat Immuneel Therapeutics |
CMC Considerations for Vector Production for T cell Therapies | GMP grade viral vectors production, CMC considerations and FDA guidelines for viral vector manufacturing. |
 |
Dr. Arkasubhra Ghosh Narayana Nethralaya Foundation |
AAV Vector Designs for Cell Therapy Applications | AAV Vector Designs, Use of AAV Vector for gene delivery. |
 |
Dr. Everette Nelson Vellore Institute of Technology |
Physiological Lentiviral Vectors for Generation of Cell Therapy Products: Challenges, Opportunities and Future Perspectives | Advantage of using physiological LVs (LVs with regulated expression) over RVs with strong promoters. |
 |
Dr. Debojyoti Chakraborty Unstitute of Genomics and Integrative Biology (CSIR-IGIB) |
Crsipr: Cell-line Engineering using Gene Editing Technologies Fast Tracking for Therapeutic Deliveries | CRISPR as a tool for faster delivery of cell based therapeutic modalities. |
 |
Dr. Raviraja N S Manipal Centre for Biotherapeutics Research |
Lack of Commercialization in Cell Therapy: Can we Achieve Harmonisation | Achieving commercialization of cell therapy where India lies far behind. |
 |
Dr. Lakshmikanth Gandikota Stempeutics |
||
| International Speaker | Talk Title | Highlights | |
|---|---|---|---|
 |
Dr. Shilpak Chatterjee CSIR- Indian Institute of Chemical technology |
T Cell Exhaustion : Reversal and Clinical Implications for Cell Therapy Use | Reversal of T cell exhaustion for longer engraftment, clinical considerations for their use. |
 |
Dr. Albeena Nisar Moderator ACTREC, Tata Memorial Centre |
Challenges in Manufacturing of CTPS & Novel Targets/ Strategies for improving the efficacy of Cell Therapies | Manufacturing challenges associated with cell therapy products, Novel targets for other cancer types and improving efficacy of cell therapy by reducing the exhaustion of T cells by ensuring longer engraftment |
 |
Dr. Hamenth Kumar Palini Christian Medical College |
||
 |
Dr. Nedun Chezhian Cytocare Technologies |
||
 |
Dr. Priyadarshini Chatterjee Aurigene Discovery Technologies |
||
 |
Dr. Priya Ramanathan Cancer Institute Adyar |
||
| International Speaker | Talk Title | Highlights | |
|---|---|---|---|
 |
Dr. Atharva Karulkar Moderator ImmunoACT |
Regulatory Advice to Guide the Development of the Next Wave of Cell Therapies & the Support from Research Funding Agencies. | Development of separate guidelines for CAR T cell therapy regulatory requirements, support from Indian research funding agencies like DBT, DST, CSIR, ICMR, etc. |
 |
Dr. Geeta Jotwani Moderator ACTREC, Tata Memorial Centre |
||
 |
Ms. Annam Visala CDSCO |
||
 |
Mr. Yogananth Rajendran Immuneel Therapeutics |
||
 |
Dr. Shashwati Basak INTAS Pharmaceuticals |
||
| International Speaker | Talk Title | Highlights | |
|---|---|---|---|
 |
Dr. Satya Yadav Moderator Medanta Hospital |
Required changes for the early accessibility of Cell Therapy: Role of Clinical Centres. | Required changes for the early accessibility of Cell Therapy: Role of Clinical Centres. |
 |
Dr. (Surg Cdr) Gaurav Narula Tata Memorial Hospital |
||
 |
Dr. Charanpreet Singh PGIMER |
||
 |
Dr. Prashant Mehta Tata Memorial Hospital |
||
|
Dr. Sunil Bhat Narayana Health Group |
||
 |
Dr. Nikita Mehra Cancer Institute Adyar |
||
 |
Dr. Uday Kulkarni Christian Medical College,Vellore |
Fully Automated Decentralized Model of Manufacturing for Clinical Trials & Scale-up Success | Decentralized model of CAR T manufacturing at point of infusion using fully automated platforms for clinical trials and their subsequent scale up. |
 |
Dr. Chetan Dhamne Tata Memorial Centre |
Natural Killer Cell Therapy and AML | NK Cells therapeutics for Acute Myeloid Leukemia |
 |
Dr. Lingraj Nayak Tata Memorial Centre |
Preparing for CAR T Cell Therapy: Patient Selection, Bridging Therapies and Lymphodepletion | Patient screening and eligibility for CAR T cell therapy, bridging therapies, need of lymphodepletion prior to CAR T infusion. |
| International Speaker | Talk Title | Highlights | |
|---|---|---|---|
 |
Dr. Akhil Kumar Aurigene |
Evolving Regulatory Landscape for CAR T & Cell Therapies -The Industry Perspective | Forming a detailed guideline for speeding up the regulatory process, having a dedicated fast track process for faster regulatory approvals. |
 |
Mr. Shirish Arya ImmunoACT |
Commercial Value of CAR T Cells in India | Commercializing CAR T cells, making it affordable and accessible for more and more patients. |
 |
Dr. Jogin Desai PGIMER |
Lack of Commercialization in Cell Therapy: Can we Achieve Harmonisation | Achieving commercialization of cell therapy where India lies far behind. |
| International Speaker | Talk Title | Highlights | |
|---|---|---|---|
 |
Mrs. Shalini Jatia Moderator ImPaCCT |
Equity, Affordability & Access to Cell Therapies | Affordability of CAR T taking into consideration the COGs and the actual market price. How affordable and accessible cell therapies can be made? |
 |
Dr. Vandana Dhamankar ImmunoACT |
||
 |
Mr. Vaggu Raghavendra Goud EMPE Diagnostics |
||
 |
Mr. Suraj Nair Ankur Capital |
||
| International Speaker | Talk Title | Highlights | |
|---|---|---|---|
 |
Dr. Rahul Purwar Moderator ImmunoACT |
Lack of Commercialization in Cell Therapy: Can we Achieve Harmonisation | Achieving commercialization of cell therapy where India lies far behind. |
 |
Dr. Satyanarayana Chava Laurus Labs |
||
